CJC-1295 (Research-Grade Peptide)
Growth Hormone-Releasing Hormone (GHRH) Analogue — for laboratory research only
Product Overview
CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH), studied for its ability to increase growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. It features a drug affinity complex (DAC) modification that extends its half-life, allowing sustained activity. Each vial contains high-purity lyophilized peptide (COA provided). Store at –20 °C and reconstitute before use following lab best practices.
Research Highlights
- GH & IGF-1 Secretion: Demonstrated sustained increases in GH and IGF-1 levels in animal and early human trials. Clinical study
- Extended Half-Life: DAC modification allows plasma half-life of up to 8 days, reducing dosing frequency in research. PubMed article
- Metabolic Effects: Shown to improve protein synthesis, lipolysis, and nitrogen retention in models. Research review
- Potential Anti-Aging Research: Investigated for maintaining growth hormone levels associated with youthful physiology. Review reference
- Combination Studies: Frequently researched in conjunction with Ipamorelin to explore synergistic GH release effects. PMC article
Product Details & Handling
- Form: Lyophilized powder
- Purity: ≥ 98% (COA provided)
- Storage: Keep at –20 °C, protect from light and moisture
- Handling: Use appropriate lab safety gear (PPE); refer to SDS for full instructions
Legal Disclaimer
This product is provided strictly for laboratory research use. It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application. Customers must comply with all applicable laws and institutional policies. CJC-1295 is not approved by the FDA or EMA for medical use. Windy City Peptide does not provide medical advice or support for human administration.